Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stock
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discovery themes featuring this stock
Investor Presentation
Q4 FY26
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
RPG Life Sciences Ltd (RPGLIFE) is currently trading at 2,109.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
RPG Life Sciences is a research-focused pharmaceutical company engaged in the development and marketing of formulations and APIs in both domestic and international markets. The company displayed a modest revenue growth of 4.0% in the 9M FY26 compared to the same period last year, although profit margins contracted due to increased expenditures. RPG Life Sciences is actively pursuing strategic capacity expansions and modernization of its manufacturing facilities, backed by a capex of ₹140 crore, to support its growth objectives. The company leverages a diversified product portfolio catering across several therapeutic segments like nephrology, oncology, cardiology, and more, with strong emphasis on chronic and specialty therapies. With zero debt and a reinforced balance sheet, the company secured a strong credit rating reaffirmation from ICRA, indicating robust financial health and sustainable growth.
Over the past 52 weeks, RPG Life Sciences Ltd has traded between a low of ₹1,731.25 and a high of ₹2,715.90. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
RPG Life Sciences Ltd has a market capitalization of approximately 3,463.68. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
RPG Life Sciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 30.07 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 3,463.68 Cr, RPG Life Sciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
RPG Life Sciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of RPG Life Sciences Ltd is 30.07. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Managing Director Ashok Nair said the company is close to acquiring a “major API asset”, while noting that API asset valuations remain elevated.
The stock rose after the company announced Q4 and FY results and its board recommended a ₹24 per share dividend for FY26.
The company reported total income of ₹666.11 crore in FY25, compared with ₹589.26 crore in FY24.
Dividend taxation notice
RPG Life Sciences informed shareholders that the Board recommended a final dividend of Rs.24 per share (300% of Rs.8) for FY2025‑26 (subject to AGM), outlined TDS/withholding rules (resident 10%; non‑resident 20%+), required documents and set a submission deadline of July 3, 2026 to the RTA.
Dividend Taxation
RPG Life Sciences notified shareholders that the Board has recommended a final dividend of Rs.24/share (300% of Rs.8) for FY2025-26 and detailed TDS/withholding rules (residents generally 10%; non-residents 20%+), required documents and a submission deadline of July 3, 2026.
KYC & Dematerialisation
RPG Life Sciences notifies shareholders holding shares in physical form to submit PAN, KYC, bank details, specimen signature and nomination to the RTA (MUFG Intime) and urges dematerialisation; provides forms/links and warns non-updation may affect dividend credit.
IEPF transfer notice
RPG Life Sciences informs shareholders that equity shares with dividends unclaimed since FY2018-19 will be transferred to the IEPF if not claimed by Sep 01, 2026; claims via MUFG Intime/RTA or IEPF‑5; physical shares will get duplicate certificates and demat holdings will be debited; details on company website.
Bearish
3
Neutral
5
Bullish
6
Bearish
29
Neutral
5
Bullish
12
Bearish
26
Neutral
0
Bullish
6
RPG Life Sciences is a research-focused pharmaceutical company engaged in the development and marketing of formulations and APIs in both domestic and international markets.
The company displayed a modest revenue growth of 4.0% in the 9M FY26 compared to the same period last year, although profit margins contracted due to increased expenditures.
RPG Life Sciences is actively pursuing strategic capacity expansions and modernization of its manufacturing facilities, backed by a capex of ₹140 crore, to support its growth objectives.
The company leverages a diversified product portfolio catering across several therapeutic segments like nephrology, oncology, cardiology, and more, with strong emphasis on chronic and specialty therapies.
With zero debt and a reinforced balance sheet, the company secured a strong credit rating reaffirmation from ICRA, indicating robust financial health and sustainable growth.
Pharmaceuticals & Biotechnology
Pharmaceuticals
3,488 Cr
Low Risk
30.3
34.1
0.6
5.7
2,715.90
1,731.25
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
132.90 | 3,901 Cr | 28.34 | 2.17 | 0.75 | 7.65 | 10.29 | 5.32 | ||
387.95 | 3,890 Cr | 60.59 | 5.85 | 0.03 | 9.66 | 11.45 | 4.78 | ||
608.45 | 3,727 Cr | -694.00 | 4.46 | 0.00 | -2.93 | -2.42 | -0.57 | ||
377.00 | 3,535 Cr | 34.66 | 4.50 | 0.11 | 12.98 | 12.14 | 6.46 | ||
2093.25 | 3,464 Cr | 30.07 | 5.72 | 1.15 | 19.03 | 24.66 | 14.52 | ||
374.00 | 3,443 Cr | 17.66 | 2.22 | 0.00 | 12.58 | 11.51 | 6.92 | ||
1311.30 | 3,288 Cr | 35.29 | 4.02 | 0.00 | 11.39 | 15.94 | 9.52 | ||
| Median: 7 Co. | — | 387.95 | 3,535 Cr | 30.07 | 4.46 | 0.03 | 11.39 | 11.51 | 6.46 |
